Business Wire

NY-AQARA

3.11.2022 09:01:35 CET | Business Wire | Press release

Share
Aqara Releases Details Around Its First Matter-Compatible Devices

Aqara, a leading provider for smart home products, shares its latest plan of Matter support and integration for its existing and new devices. Aqara is fully committed to supporting Matter, and the Company has been working with the Connectivity Standards Alliance (CSA) and key stakeholders such as Apple, Google and Samsung on early testing programs to ensure a smooth transition towards the new standard. Aqara users will first gain access to Matter in December 2022 via the Aqara Hub M2 through an OTA (over-the-air) update, which will allow existing Aqara Zigbee devices to become compatible with Matter.

Other Aqara hubs, including the Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3, and Camera Hub G2H Pro, will also receive similar OTA updates in the following months so that more Aqara users will be able to enjoy the benefits of Matter. The software updates are expected to first expose more than 40 Aqara Zigbee devices ranging from smart sensors and wireless switches to controller-type devices such as radiator thermostats and curtain controllers*. Through the Aqara hubs, these devices will be able to support Matter and connect with other third-party Matter devices. Some of these devices are listed below:

  • Door & Window Sensor
  • Temperature & Humidity Sensor
  • Motion Sensor and Motion Sensor P1
  • Vibration Sensor
  • Smart Wall Switch (US)
  • Smart Wall Switch H1 EU
  • Smart Plug (US & EU)
  • Single Switch Module T1
  • Wireless Mini Switch
  • Wireless Remote Switch H1
  • Wireless Remote Switch (Single & Double Rocker)
  • Radiator Thermostat E1
  • Roller Shade Driver E1
  • Curtain Driver E1
  • Roller Shade Controller (Zigbee 1.2)
  • LED Bulb and LED Bulb T1 (Tunable White)

Aqara aims to provide a comprehensive suite of Matter-compatible devices to global users, and its Matter device portfolio will continue to grow and incorporate other existing Zigbee devices in the coming future. Ultimately more than 160 Aqara Zigbee products belonging to over 10 different device categories are expected to receive Matter support.

Moreover, a new lineup of Thread-based devices will be introduced. Building upon the success of Aqara’s iconic door and window sensor as well as the motion sensor, the Company will refresh the designs of these two devices to adopt the Thread protocol - among other enhancements - to allow for native Matter support and direct connection with Matter controllers. The new sensors, i.e. the Door and Window Sensor P2 and the Motion and Light Sensor P2, are set to release in early 2023. As part of the ongoing partnership between NXP Semiconductors and Aqara, the Aqara Thread sensor will be showcased at the NXP demo table on the Matter launch event in Amsterdam.

An array of Thread-based Aqara devices is to follow including various smart sensors, dimmer switches, smart plugs, lights, and the next-gen smart home hub with multi-protocol support. The Aqara Hub M3 is designed to not only allow Aqara Zigbee devices to support Matter, but also serve as a Thread Border Router and a Matter Controller and Commissioner, which can directly connect and manage Thread and Matter-compatible smart home devices. The Company also plans to open its Aqara Home app to support third-party Matter devices.

Aqara strives to offer high-quality, smart home solutions that are accessible to everyone, specifically focusing on creating a seamless user experience. The Matter standard undoubtedly raises connected home experiences to the next level with unprecedented interoperability and simplicity, and Aqara will continue to enrich its Matter portfolio to offer users even more options for their smart homes and to expedite the mass adoption of smart homes worldwide.

* A full list of the first Aqara Zigbee devices to receive Matter support is available here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005123/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release

Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release

Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release

Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release

Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye